133 related articles for article (PubMed ID: 28970367)
1. A Pilot Study of OkKidney, a Phosphate Counting Application in Patients on Peritoneal Dialysis.
Imtiaz R; Atkinson K; Guerinet J; Wilson K; Leidecker J; Zimmerman D
Perit Dial Int; 2017; 37(6):613-618. PubMed ID: 28970367
[TBL] [Abstract][Full Text] [Related]
2. Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.
Imtiaz R; Hawken S; McCormick BB; Leung S; Hiremath S; Zimmerman DL
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28218647
[TBL] [Abstract][Full Text] [Related]
3. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
Leung S; McCormick B; Wagner J; Biyani M; Lavoie S; Imtiaz R; Zimmerman D
BMC Nephrol; 2015 Dec; 16():205. PubMed ID: 26645271
[TBL] [Abstract][Full Text] [Related]
4. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
[TBL] [Abstract][Full Text] [Related]
5. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
6. MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.
Evsanaa B; Liu I; Aliazardeh B; Mahdavi S; Bajwa G; Gula J; Tam M; Sze E; Roscoe JM; Tam PY; Sikaneta T
Perit Dial Int; 2015; 35(1):31-4. PubMed ID: 24584605
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary Team versus a "Phosphate-Counting" App for Serum Phosphate Control: A Randomized Controlled Trial.
Farfan-Ruiz AC; Czikk D; Leidecker J; Ramsay T; McCormick B; Wilson K; Zimmerman D
Kidney360; 2021 Feb; 2(2):290-297. PubMed ID: 35373021
[TBL] [Abstract][Full Text] [Related]
8. Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis.
Jiang N; Fang W; Gu AP; Yuan JZ; Yang XX; Lin AW; Ni ZH; Qian JQ
Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):846-852. PubMed ID: 26141941
[TBL] [Abstract][Full Text] [Related]
9. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
10. Calcium carbonate as a phosphate binder: is there a need to adjust peritoneal dialysate calcium concentrations for patients using CaCO3?
Martis L; Serkes KD; Nolph KD
Perit Dial Int; 1989; 9(4):325-8. PubMed ID: 2488389
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Shigematsu T; Negi S;
Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis.
Bernardo AP; Contesse SA; Bajo MA; Rodrigues A; Del Peso G; Ossorio M; Cabrita A; Selgas R
Clin J Am Soc Nephrol; 2011 Mar; 6(3):591-7. PubMed ID: 21115631
[TBL] [Abstract][Full Text] [Related]
13. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
14. Calcium carbonate powder as a phosphate binder.
Miller D; Taber TE; Hegeman TF
ASAIO Trans; 1989; 35(3):322-4. PubMed ID: 2597473
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Yamada S; Yoshida H; Taniguchi M; Tanaka S; Eriguchi M; Nakano T; Tsuruya K; Kitazono T
Intern Med; 2012; 51(16):2097-104. PubMed ID: 22892485
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
17. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
[TBL] [Abstract][Full Text] [Related]
18. Low calcium dialysate and hyperparathyroidism.
Duncan R; Cochrane T; Bhalla C; Michael J; Richards NT; Adu D
Perit Dial Int; 1996; 16 Suppl 1():S499-502. PubMed ID: 8728256
[TBL] [Abstract][Full Text] [Related]
19. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
20. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
Weinreich T; Passlick-Deetjen J; Ritz E
Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
